Multi-layered polymer film for sustained release of agents
US-2024226394-A1 · Jul 11, 2024 · US
US10034968B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10034968-B2 |
| Application number | US-201715427809-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2017 |
| Priority date | Nov 8, 2013 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in a patient in need thereof. In one embodiment, the matrix comprises a first porous layer comprising collagen and a second porous layer comprising collagen and dextran, wherein the dextran is loaded in the second layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix. In some embodiments, the matrix prevents or reduces cell growth into the matrix so as to reduce or prevent adhesions. In some embodiments, the matrix is in a sheet or strip form that can be folded into a tube form.
Opening claim text (preview).
What is claimed is: 1. A foldable or flexible biodegradable polymer matrix for reducing, preventing or treating adhesions in a patient in need thereof, the matrix comprising a first layer comprising collagen; a second layer comprising dense collagen; and a third layer comprising collagen and dextran, wherein the dextran is loaded in the third layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix, and the matrix is configured to be folded into a wrap configuration such that the third layer is on the outside of the wrap and the first layer is on the inside of the wrap and the second layer is disposed between the first layer and the third layer; and the matrix is configured to release from about 5% to about 90% of the dextran loaded in the matrix, wherein the first layer comprises pores that have a pore size from about 250 to about 1000 microns, wherein the matrix is folded into a wrap configuration and the third layer is less porous than the first layer but is more porous than the second layer. 2. A matrix of claim 1 , wherein the matrix (i) is a multi-layered sheet; (ii) is a multi-layered sponge; (iii) is in tubular form; (iv) is in strip or sheet form; (v); the matrix reduces cell growth into the matrix by retaining dextran; or (vi) the matrix is configured to release from about 20% to about 90% of the dextran loaded in the matrix within 24 to 48 hours. 3. A matrix of claim 1 , wherein the dextran comprises dextran sulfate comprising from about 5.0 wt. % to about 70 wt. % of the matrix and the content of dextran sulfate is from about 0.5% to about 2.0% by weight. 4. A matrix of claim 1 , wherein the first layer is porous to facilitate cell infiltration and attachment to the first layer and the first layer comprises pores having a pore size from about 250 to about 500 microns. 5. A matrix of claim 1 , wherein the second layer is non-porous and prevents diffusion of the dextran into the first layer. 6. A matrix of claim 1 , wherein the third layer comprises pores that have a pore size from about 0.05 to about 200 microns. 7. A matrix of claim 1 , wherein the second layer and the third layer comprise pores that have a pore size from about 0.05 to about 200 microns, the first layer being more porous than the third layer, the dextran being loaded in the second layer and the third layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix and the dextran configured to release from about 5% to about 90% within 24 to 48 hours and the matrix reduces cell growth therein, wherein the third layer is the outer most layer.
cylindrical · CPC title
Implantable repair or support meshes, e.g. hernia meshes · CPC title
Hydrogels or hydrocolloids · CPC title
Macromolecular materials · CPC title
Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.